Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
08:03am, Thursday, 03'rd Jul 2025
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high
FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial
06:45am, Wednesday, 02'nd Jul 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priori
Top 15 High-Growth Dividend Stocks For July 2025
09:02pm, Tuesday, 01'st Jul 2025
My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in June, gaining 6.15% versus SPY's 5.14% and VIG's 3.41%. The list's year-to-date return is 12.59%, beating SPY every month in 2025, tho
Trading Rotation Kicks Off 2nd Half of 2025
07:11pm, Tuesday, 01'st Jul 2025
Tech stocks lagged after a very strong first half of the year, while healthcare led the way.
Top 10 High-Yield Dividend Stocks For July 2025
02:06pm, Tuesday, 01'st Jul 2025
My July 2025 watchlist focuses on high-yield, attractively valued stocks, aiming for a 12% long-term CAGR and outperforming benchmarks. Since its inception, my watchlist has a CAGR of 15.11%, performi
Dividend Yield Theory Says Merck Is A Buy
01:57pm, Tuesday, 01'st Jul 2025
Dividend Yield Theory identifies Merck & Co., Inc. as undervalued, with a 4.09% yield well above its historical mean, suggesting strong total return potential. Despite Keytruda's looming patent expira
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
01:10pm, Tuesday, 01'st Jul 2025
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
DUBAI, United Arab Emirates--(BUSINESS WIRE)-- #CEO--Merck Foundation conducted the 7th Edition of Merck Foundation First Ladies Initiative - MFFLI Summit 2025 in Dubai, United Arab Emirates.
Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29
06:45am, Tuesday, 01'st Jul 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29.
Merck: Don't Let Today's Bargain Opportunity Pass You By
03:38am, Sunday, 29'th Jun 2025
Merck: Don't Let Today's Bargain Opportunity Pass You By
Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade)
01:36pm, Friday, 27'th Jun 2025
Merck & Co., Inc.'s heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Valuation has become attractive after a significant s
40% Upside For Merck Stock?
07:05am, Friday, 27'th Jun 2025
Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically positioning itself for further growth by diversifying and expanding its pipelin
Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know
06:51pm, Thursday, 26'th Jun 2025
Merck (MRK) closed the most recent trading day at $78.83, moving 1.05% from the previous trading session.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--ACIP Recommends Merck's ENFLONSIA for Prevention of RSV in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season.
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
10:51am, Thursday, 26'th Jun 2025
Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.
